RE:RE:RE:RE:Pipeline: Pre-Launch Drugs at KnightMrMugsy wrote: OK - so product that is identified as "pre-registered" or "submitted" are the only products in the queue that are NOT making money yet. They are the real pipeline on this document. That makes our pipeline ... 13 drug x countries at this time.
Everything else is making money - and EXELON is making money on a side deal with Novartis, until the drug transfers are done.
Thanks Gudisgood.
MrMugsy wrote: gudisgood wrote: MrMugsy,
Not sure if you saw my previous post about this.
Perhaps I have this wrong, but if you look at the latest Annual Information Form (page 30), they define Launched and Marketed the following way:
Launched: product has been on the market under 5 years Marketed: product has been on the market over 5 years
Source: https://www.gud-knight.com/wp-content/uploads/AIF-2020_VF.pdf
Interesting Gudisgood and I see the order at the bottom of the product spreadsheet showing
Launched before marketed - to your point, that would make sense.
This is a little confusing as we're not making money from EXELON sales yet as we wait for tranfers to be completed. From this I assumed the drug would go to "launched" after we are selling. Likely not the case based on what you are saying.
Getting confused.
No problem!
Yes, the status of the drug (launched or marketed) only tells us about the maturity level of the drug in the market - regardless of how long GUD's been involved with it. Whether and how GUD is making money with Exelon, for instance, is irrelevant, since the drug itself has been sold in this market for a long time... so it's "marketed" even though our marketing efforts are only about to begin.